|
Prostatic Neoplasms
|
0.600 |
PosttranslationalModification
|
group |
LHGDN |
Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation.
|
17606718 |
2007 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
The role of PTEN in prostate cancer cell tropism to the bone micro-environment.
|
17347137 |
2007 |
|
Prostatic Neoplasms
|
0.600 |
GeneticVariation
|
group |
LHGDN |
PTEN mutations do not cause nuclear beta-catenin accumulation in endometrial carcinomas.
|
15492994 |
2004 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
[Role of PTEN protein in multidrug resistance of prostate cancer cells].
|
18702307 |
2008 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Integrative molecular concept modeling of prostate cancer progression.
|
17173048 |
2007 |
|
Prostatic Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
To further define the role of PTEN/MMAC1 in the development of prostate cancer and its spectrum of genetic alterations, we analysed 40 pT2 or pT3 prostate tumors for allelic loss, mutations, and homozygous deletions using PCR-based methods.
|
9788441 |
1998 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer.
|
17372210 |
2007 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced prostate carcinogenesis in CYP1A-humanized mice.
|
22581815 |
2012 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Pten inactivation and the emergence of androgen-independent prostate cancer.
|
17638861 |
2007 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
This report describes a novel mouse model that overexpresses ERG and lacks PTEN with the majority of mice developing prostate tumors by 6 mo.
|
25007053 |
2014 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
Downregulation of PTEN/MMAC/TEP1 expression in human prostate cancer cell line DU145 by growth stimuli.
|
12190124 |
2002 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
We have quantitatively analyzed the mRNA levels of TMPRSS2-ERG, ERG, PTEN, and AR (n = 83), as well as ERG immunostaining (n = 78) in a series of prostate tumors.
|
25939480 |
2015 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss.
|
16697957 |
2006 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation.
|
16432235 |
2006 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Furthermore, ADT combined with vaccination, specifically a DNA vaccine encoding the ligand-binding domain of the AR, led to improved antitumor responses as measured by tumor volumes and delays in the emergence of castrate-resistant prostate tumors in two murine prostate cancer models (Myc-CaP and prostate-specific PTEN-deficient mice).
|
29051161 |
2017 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival.
|
12429629 |
2002 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
The PTEN gene, located on 10q23, has recently been implicated as a candidate tumor suppressor gene in brain, breast and prostate tumors.
|
9331072 |
1997 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Here, we show that AKT2 is exclusively required for PTEN-deficient prostate tumor spheroid maintenance, whereas AKT1 is dispensable. shRNA silencing of AKT2 but not AKT1 promotes regression of prostate cancer xenografts.
|
24838891 |
2014 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer.
|
16421604 |
2006 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Furthermore, we showed in preclinical models that BRG1 antagonist selectively inhibited the progression of PTEN-deficient prostate tumors.
|
30496141 |
2019 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.
|
29295717 |
2018 |
|
Prostatic Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
One somatic mutation (17%), a 1 bp deletion, was detected in exon 7 of the gene, in one tumor, indicating that somatic mutations of the PTEN gene may occur in primary prostate tumors.
|
9671408 |
1998 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Retroviral expression of constitutively active Notch-1 in human prostate tumor cell lines resulted in increased PTEN gene expression.
|
19479935 |
2009 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
|
17826033 |
2007 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is lost as a function of prostate tumor androgen dependence.
|
16637073 |
2006 |